Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ: ARWR )

20.76 -0.77 (-3.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
Via Benzinga
The Latest Analyst Ratings for Arrowhead Pharma
Via Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases. 
Via The Motley Fool
Is Arrowhead Pharmaceuticals a Buy Now?
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts. 
Via The Motley Fool
Expert Ratings for Arrowhead Pharma
Via Benzinga
Analyst Ratings for Arrowhead Pharma
Via Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars
Via Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Earnings Outlook For Arrowhead Pharmaceuticals
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Arrowhead Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
Via Benzinga
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
Via Benzinga
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54. 
Via Benzinga
Energizer, Children's Place And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Earnings Scheduled For February 6, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion. 
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Via Benzinga
Why Arrowhead Pharmaceuticals Stock Is Diving Today
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) shares are down 20% Monday after the company announced topline results from the SEQUOIA Phase 2 study of fazirsiran in patients with 
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
The company says it plans soon to present Phase 2 results and its Phase 3 study design. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.